Salud financiera de hoja de balance de Supernus Pharmaceuticals
Salud financiera controles de criterios 6/6
Supernus Pharmaceuticals tiene un patrimonio de accionistas total de $921.5M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $1.3B y $356.2M respectivamente. El BAIT de Supernus Pharmaceuticals es de $13.4M, por lo que su ratio de cobertura de intereses es de -1.7. Tiene efectivo e inversiones a corto plazo que ascienden a $254.9M.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | -0.7x |
| Efectivo | US$297.74m |
| Patrimonio | US$929.17m |
| Total pasivo | US$374.92m |
| Activos totales | US$1.30b |
Actualizaciones recientes sobre salud financiera
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?
Oct 19Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly
Jul 05Recent updates
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Oct 10Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Aug 19Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear
Aug 16Supernus: A Work In Progress
Jul 29Supernus: New Beginnings
Mar 28Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts
Dec 02Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?
Nov 30Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?
Oct 19Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?
Aug 31Supernus: Well Prepared For Upcoming Challenges
Aug 26Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly
Jul 05Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($493.1M) de SUPN superan a sus pasivos a corto plazo ($290.2M).
Pasivo a largo plazo: Los activos a corto plazo de SUPN ($493.1M) superan a sus pasivos a largo plazo ($66.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: SUPN está libre de deudas.
Reducción de la deuda: SUPN no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 78.2%.
Cobertura de la deuda: SUPN no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: SUPN no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.